In the long human search for relief from depression's weight, science occasionally finds unexpected candidates in familiar places. Creatine — a compound already trusted by athletes and found in everyday foods — has now been examined across five clinical trials for its potential to ease depressive symptoms, with results that neither confirm nor dismiss the possibility. Researchers in Ottawa and beyond are left holding a question that is genuinely worth asking, but not yet ready to be answered.
Creatine Shows Promise for Depression, But Evidence Remains Inconclusive
The signal is interesting, but it is not a verdict.
Mark
So we have two studies showing creatine helps depression, and three showing it doesn't. Why is that split so important?
Mimi
Because clinical practice changes only when the evidence is overwhelming. Two positive trials out of five is not overwhelming. It's a signal, but it could be noise.
Luke
Are the two positive trials and the three negative trials actually comparable? Same dose? Same duration? Same population?
Mimi
The review doesn't detail that level of methodological comparison, so we don't know if the differences in outcome reflect real differences in how the studies were designed.
Mark
What about the two people with bipolar disorder who developed mania? Is that a red flag?
Mimi
It's a flag, yes. Two cases in a review of 238 people is a small number, but mania is serious. You can't ignore it.
Luke
But you also can't prove creatine caused it. Those two people might have developed mania anyway.
Mimi
Exactly. That's why the researchers are calling for larger studies. You need bigger numbers to separate signal from coincidence.
Mark
So what happens now? Do people stop taking creatine for depression?
Mimi
Most people aren't taking it for depression in the first place. It's used for muscle. But if someone is considering it as an add-on to their antidepressant, this review suggests they should talk to their doctor first.
Luke
And the doctor would say what? The evidence is mixed?
Mimi
Yes. And if you have bipolar disorder, the risk of mood destabilization might outweigh any potential benefit.
El Pulso
- The promise is real but fractured: two trials showed creatine meaningfully boosted antidepressant medication and therapy outcomes, while three others found no benefit whatsoever.
- A safety signal has emerged that cannot be ignored — two participants with bipolar disorder developed hypomania or mania, serious episodes that can require hospitalization.
- The 238-person sample spread across five trials is simply too small and too inconsistent to support any clinical guidance, leaving clinicians with no actionable path forward.
- Lead researcher Bassam Jeryous Fares is urging the field toward larger, longer, more rigorous studies before creatine can be considered anything more than a psychiatric curiosity.
In the long human search for relief from depression's weight, science occasionally finds unexpected candidates in familiar places. Creatine — a compound already trusted by athletes and found in everyday foods — has now been examined across five clinical trials for its potential to ease depressive symptoms, with results that neither confirm nor dismiss the possibility. Researchers in Ottawa and beyond are left holding a question that is genuinely worth asking, but not yet ready to be answered.
Creatine is a compound the body produces naturally and that millions already take to build muscle and sharpen athletic performance. Now a new review is asking whether it might also have a role in treating depression — a question rooted in the logic that if creatine fuels energy in muscle cells, it may do something similar in the brain.
Published in Brain Medicine on June 30, the review examined five randomized clinical trials enrolling 238 people diagnosed with depression or bipolar disorder. The results were deeply divided. Two trials involving major depressive disorder patients showed genuine promise: one found that adding creatine to the antidepressant escitalopram produced better outcomes than the medication alone, and another found it enhanced the effects of cognitive behavioral therapy. But three remaining trials, including one focused on bipolar disorder, found no benefit at all.
Safety data added another layer of complexity. Most participants tolerated creatine well, reporting only mild gastrointestinal discomfort. However, two participants with bipolar disorder developed hypomania or mania — serious mood episodes that can require hospitalization. Whether creatine triggered these episodes or whether they would have occurred regardless remains unknown, but the signal is considered significant enough to warrant careful attention.
Lead author Bassam Jeryous Fares, a medical student at the University of Ottawa, was measured in his conclusions: the evidence is interesting, but two trials pointing one way and three pointing another does not constitute grounds for changing clinical practice. What it does justify, he argued, is more research — larger studies with longer follow-up and clearer protocols. For now, creatine remains a compelling question in psychiatry, not yet an answer.
Creatine is a compound your body produces naturally, and it shows up in meat, fish, and poultry. Millions of people take it as a supplement to build muscle and boost athletic performance. Now researchers are asking whether it might also ease depression.
A review published June 30 in Brain Medicine examined five randomized clinical trials that enrolled 238 people diagnosed with depression or bipolar disorder. The question driving the research is straightforward: if creatine fuels energy production in muscle cells, could it do something similar in the brain, where mood and mental function live?
The results split down the middle. Two trials in people with major depressive disorder showed promise. In one study, adding creatine to the antidepressant escitalopram produced better symptom improvement than the medication alone. A second trial found that creatine enhanced the effects of cognitive behavioral therapy, a talk-based treatment for depression. But three other trials—including one focused on bipolar disorder—found no benefit at all. The mixed picture is what makes the findings so difficult to interpret. You cannot build a treatment recommendation on evidence that points in two directions simultaneously.
Safety data offered some reassurance. Most people tolerated creatine well, experiencing only mild gastrointestinal discomfort. But the review also flagged a concern: two participants with bipolar disorder developed hypomania or mania while taking the supplement. These are serious mood episodes that can require hospitalization. The small number makes it impossible to know whether creatine triggered these cases or whether they would have occurred anyway, but the signal is real enough to warrant attention.
Bassam Jeryous Fares, a medical student at the University of Ottawa and the lead author of the review, framed the findings with appropriate caution. The evidence is interesting, he said, but it is not conclusive. Two trials pointed one direction, three pointed another. That pattern does not justify changing how doctors treat depression. What it does justify is more research—larger studies, longer follow-up periods, clearer protocols. The question itself is worth asking again, with better tools and bigger sample sizes. Until then, creatine remains a curiosity in psychiatry, not a remedy.
Citas Notables
The signal is interesting, but it is not a verdict. Two trials pointed one way and three pointed another. That is not the kind of evidence on which you change clinical practice.— Bassam Jeryous Fares, medical student at the University of Ottawa
Quieres la nota completa?
Lee el original en Medical Xpress ↗
Health & Medicine